Skip to main content
. 2018 Dec 18;18:390. doi: 10.1186/s12888-018-1952-z

Table 2.

Characteristics of bipolar patients with metabolic syndrome and hyperuricemia

Variable Metabolic syndrome Hyperuricemia
Yes (n = 135) No (n = 183) p Yes (n = 86) No (n = 232) p
Age (years) 44.1 (12.5) 35.4 (12.6) < 0.001 40.5 (13.4) 38.6 (13.0) 0.265
Male, n (%) 67 (49.6) 83 (45.4) 0.450 50 (56.8) 100 (43.5) 0.033
Education (years) 11.5 (3.6) 12.10 (3.4) 0.104 11.4 (3.2) 12.0 (3.5) 0.150
Smoker, n (%) 42 (31.1) 44 (24.0) 0.161 26 (29.5) 60 (26.1) 0.534
Married, n (%) 83 (61.5) 92 (50.3) 0.047 47 (53.4) 128 (55.7) 0.719
Illness duration (year) 15.9 (11.3) 9.9 (9.3) < 0.001 14.25 (10.6) 11.9 (10.6) 0.013
Over weight, n (%) 85 (63.0) 60 (32.8) < 0.001 52 (59.1) 93 (40.4) 0.003
Illness episode, n (%) 0.012 0.001
 Manic/hypomanic 91 (67.4) 104 (56.8) 68 (77.3) 127 (55.2)
 Depressive 31 (23.0) 69 (37.7) 14 (15.9) 86 (37.4)
 Mixed 5(3.7) 1 (0.5) 3 (3.4) 3 (1.3)
 Euthymic 8(5.9) 9(4.9) 3 (3.4) 14 (6.1)
BPD type II, n (%) 9 (6.7) 12 (6.6) 0.969 6 (6.8) 15 (6.5) 0.924
Antipsychotics use, n (%) 120 (88.9) 135 (73.8) 0.001 72 (81.8) 183 (79.6) 0.652
CPZ equivalents (mg/d) 344.7 (205.9) 297.7 (248.1) 0.030 3602 (209.8) 307.0 (236.1) 0.081
Mood stabilizer use, n (%) 118 (87.4) 144 (78.7) 0.044 74 (84.1) 188 (81.7) 0.662

Data were mean ± SD unless otherwise indicated. BPD bipolar disorder, CPZ chlorpromazine